A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

SmartNuclide Biopharma1 个研究点分布在 1 个国家目标入组 12 人开始时间: 2025年10月1日最近更新: 2026年5月19日

适应症

试验速览

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

•Aged between 18 and 75 years (inclusive);
•Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
•Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
•Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
•Pathology test results from within the past year;

•Patients with other clearly diagnosed malignant tumours;
•Patients with uncontrolled severe infections, or those with other serious comorbidities;
•Patients with a life expectancy of ≤3 months;
•Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
•Patients deemed unsuitable for participation in this study by the investigator.

发起方

SmartNuclide Biopharma

申办方类型

Industry

责任方

Sponsor

Loading locations...